Office-Based Buprenorphine Treatment for Opioid-Dependent Patients

REFERENCES

• Substance Abuse and Mental Health Services Administration, Office of Applied Studies, New heroin users admitted to treatment. 1992–2000, DASIS Report, October 10, 2003. At. http://oas.samhsa.gov/dasis.htm
   Google Scholar
• Johnston L D, O'Malley P M, Bachman J G, Schulenberg J E. Monitoring the Future: national results on adolescent drug use: overview of key findings. 2003, [NIH pub. no. 04–5506]. Bethesda, MD, National Institute on Drug Abuse. 2004
   Google Scholar
• Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Emergency department data from the Drug Abuse Warning Network: final estimates 1995–2002 [DAWN series D-24; DHHS pub. no. (SMA) 03–3780)]. Rockville, MD, SAMHSA OAS. 2003
   Google Scholar
• Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Mortality data from the Drug Abuse Warning Network: 2002 [DAWN series D-25; DHHS pub. no. 04–3875]. Rockville, MD, SAMHSA OAS. 2004
   Google Scholar
• Bickel W K, Amass L. Buprenorphine treatment of opioid dependence: a review. Exp Clin Psychopharmacol. 1995; 3: 477–89
   Web of Science ®Google Scholar
• Walsh S L, Preston K L, Stitzer M L, Cone E J, Bigelow G E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994; 55: 569–80. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Harris D S, Jones R T, Welm S, Upton R A, Lin E, Mendelson J.. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 2000; 61: 85–94. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• McCance-Katz E F, Kosten T R. Psychopharmacological treatments. Miller S, Frances R. Clinical textbook of addictive disorders. New York, Guilford. 1998; 596–624
   Google Scholar
• Kleber H D. Pharmacologic treatments for heroin and cocaine dependence. Am J Addict. 2003; 12, (suppl). S1–4
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Cohen H, Atias S. Outcomes of naltrexone maintenance following ultra rapid opiate detoxification versus intensive inpatient detoxification. Am J Addict. 2002; 11: 52–6. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kleber H D. Detoxification from narcotics. Lowinson J H, Ruiz P. Substance abuse: clinical problems and perspectives. Baltimore, MD, William & Wilkins. 1981; 317–38
   Google Scholar
• Center for Substance Abuse Treatment. State Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series 1. DHHS pub. no. (SMA) 93–1991. Rockville, MD, US Department of Health and Human Services. 1993
   Google Scholar
• Center for Substance Abuse Treatment, Expert panel clinical guidelines on LAAM in opioid agonist therapy (OAT) [Technical Assistance Publication Series; on file with author]
   Google Scholar
• Ball J, Ross A. The effectiveness of methadone maintenance treatment. New York, Springer-Verlag. 1991
   Google Scholar
• Tamaskar R, Parran T V, Jr, Heggi A, Brateanu A, Rabb M, Yu J. Tramadol versus buprenorphine for the treatment of opiate withdrawal: a retrospective cohort control study. J Addict Dis. 2003; 22(4)5–12. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Schottenfeld R S, Pakes J, O'Connor P, Chawarski M, Oliveto A, Kosten T R. Thrice weekly versus daily buprenorphine. Biol Psychiatry. 2000; 47: 1072–9. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• O'Connor P G, Kosten T R. Management of opioid intoxication and withdrawal. Graham A W, Schultz T K. Principles of addiction medicine. Chevy Chase, MD, American Society of Addiction Medicine. 1998; 457–64
   Google Scholar
• Strain E C, Stitzer M L, Liebson I A, Bigelow G E. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and Addiction Severity Index. J Clin Psychopharmacol. 1996; 16: 58–67. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Jaffe J H, Knapp C M, Ciraulo D A. Opiates: clinical aspects. Lowinson J H, Ruiz P, Millman R B, Langrod J G. Substance abuse: a comprehensive textbook. Baltimore, MD, Williams & Wilkins. 1997; 158–66
   Google Scholar
• Johnson R E, Chutuape M A, Strain E C, Walsh S L, Stitzer M L, Bigelow G E. A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. N Engl J Med. 2000; 343: 1290–7. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Fudala P J, Bridge T P, Herbert S, et al, Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349: 949–58. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mee-Lee D. ASAM patient placement criteria for the treatment of substance-related disorders, 2nd ed. rev.. Chevy Chase, MD, American Society of Addiction Medicine. 2001
   Google Scholar
• Petry N M, Bickel W K, Piasecki D, Marsch L A, Badger G J. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict. 2000; 9: 265–9. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, Washington, DC, APA. 2000
   Google Scholar
• McNicholas L.. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: a treatment improvement protocol (TIP 40). Rockville, MD, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. 2004
   Google Scholar
• Handlesman L, Cochrane K J, Aronson M J, Ness R, Rubinstein K J, Kanof P D. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987; 13: 293–308. [CSA]
   PubMed Web of Science ®Google Scholar
• Wesson D R, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003; 35: 253–9. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Physicians' Desk Reference. 58th ed. Subutex/Suboxone package insert. Montvale, NJ, Thomson Healthcare. 2004
   Google Scholar
• Amass L, Bickel W K, Higgins S T, Hughes J R. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis. 1994; 13(3)33–45. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kakko J, Svanborg K D, Kreek M J, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet. 2003; 361: 662–8. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bickel W K, Stitzer M I, Bigelow G E, Liebson I A, Jasinski D R, Johnson R E. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther. 1988; 43: 72–8. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Cheskin L J, Fudala P J, Johnson R E. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend. 1994; 36: 115–21. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nigam A, Ray R, Tripathi B M. Buprenorphine in opiate withdrawal: a comparison with clonidine. J Subst Abuse Treat. 1993; 10: 391–4. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• O'Connor P G, Carroll K M, Shi J M, Schottenfeld R S, Kosten T R, Rounsaville B J. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med. 1997; 127: 526–30. [CSA]
   PubMed Web of Science ®Google Scholar
• Hansen G R, Leshner A I, Tai B. Putting drug abuse research to use in real life settings. J Subst Abuse Treat. 2002; 23: 69–70. [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Amass L, Ling W, Freese T E, Reiber C, Annon J J, Cohen A J. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict. 2004; 13, (suppl 1). S42–66. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McCance-Katz E F, Kosten T R. Psychopharmacological treatments. Miller S, Frances R. Clinical textbook of addictive disorders, 3rd ed, New York, Guilford, (in press).
   Google Scholar
• Krantz M J, Mehler P S. Treating opioid dependence. Growing implications for primary care. Arch Intern Med. 2004; 164: 277–88
   PubMed Web of Science ®Google Scholar
• Gourevitch M N, Friedland G F. Interactions between methadone and medications used to treat HIV infection: a review. Mt Sinai J Med. 2000; 67: 429–36. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• McCance-Katz E F, Gourevitch M N, Arnsten J, Sarlo J, Rainey P, Jatlow P. Modified Directly Observed Therapy (MDOT) for injection drug users with HIV disease. Am J Addict. 2002; 11: 271–8. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• McCance-Katz E F, Rainey P, Friedland G, Jatlow P. The protease inhibitor lopinavir/ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis. 2003; 37: 476–82. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McCance-Katz E F, Rainey P M, Smith P, et al, Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am J Addict, (in press).
   Web of Science ®Google Scholar
• Karin H, Segerdahi M, Gustafsson L L, Kalso E.. Methadone, ciprofloxacin and adverse drug reactions. Lancet. 2000; 356: 2069–70. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Iribarne C, Berthou F, Baird S, et al, Involvement of cytochrome P450 3A4 enzyme in the n-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996; 9: 365–73. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Iribarne C, Picart D, Dreano Y, Bail J P, Berthou F. Involvement of cytochrome P450 3A4 in n-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997; 60: 1953–64. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McCance-Katz E F, Pade P, Exhem-Williams C, Hellew L, Moody D, Rainey P M. Concomitant administration of buprenorphine and efavirenz is not associated with opiate abstinence symptoms in opioid dependent individuals. Drug Alcohol Depend, (in press).
   Google Scholar
• Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti J P. Injecting misuse of buprenorphine among French drug users. Addiction. 2001; 96: 267–72. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend. 2003; 69: 175–81. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kintz P. A new series of 13 buprenorphine-related deaths. Clin Biochem. 2002; 35: 513–6. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Boyd J, Randell T, Luurila H, Kuisma M. Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand. 2003; 47: 1031–3. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gal J T. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther. 1989; 45: 66–71. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Johnson R E, Jones H E, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 2003; 70: S87–101. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Marquet P, Chevrel J, Lavignasse P, Merle L, Lachatre G. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther. 1997; 62: 569–71. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Marquet P, Lavignasse P, Chevrel J, Lachatre G, Merle L. In utero exposure to Subutex induces no or mild withdrawal syndromes in the newborn. Therapie. 1998; 53: 178
   Google Scholar
• Vestal R E, Cusack B J. Interactions in the elderly. Levy R H, Thummel K E, Trager W F, Hansten P D, Eichelbaum M. Metabolic drug interactions. Philadelphia, Lippincott Williams & Wilkins. 2000; 730–4
   Google Scholar
• Johnson R E, Fudala P J, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage, (in press).
   Web of Science ®Google Scholar
• Watson P JQ, McQuay H J, Bullingham R E, Allen M C, Moore R A. Single-dose comparison of buprenorphine 0.3 and 0.6 mg i.v. given after operation: clinical effects and plasma concentration. Br J Anaesth. 1982; 54: 37–43
   Google Scholar
• Bullingham R E, McQuay H J, Dwyer D, Allen M C, Moore R A. Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol. 1981; 12: 117–22. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Summerfield R J, Allen M C, Moore R A, Sear J W, McQuay H J. Buprenorphine in end stage renal failure [Letter]. Anaesthesia. 1985; 41: 914
   Google Scholar